Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is -1.35% lower on its value in year-to-date trading and has touched a low of $37.02 and a high of $60.37 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RARE stock was last observed hovering at around $41.15 in the last trading session, with the day’s gains setting it 0.35%.
Currently trading at $41.50, the stock is -7.73% and -12.70% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.48 million and changing 0.85% at the moment leaves the stock -12.92% off its SMA200. RARE registered -13.45% loss for a year compared to 6-month gain of 1.52%. The firm has a 50-day simple moving average (SMA 50) of $47.5384 and a 200-day simple moving average (SMA200) of $47.659.
The stock witnessed a -11.08% loss in the last 1 month and extending the period to 3 months gives it a -22.66%, and is -5.29% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.19% over the week and 3.92% over the month.
Ultragenyx Pharmaceutical Inc (RARE) has around 1276 employees, a market worth around $3.86B and $522.75M in sales. Profit margin for the company is -106.93%. Distance from 52-week low is 12.10% and -31.26% from its 52-week high. The company has generated returns on investments over the last 12 months (-46.58%).
with sales reaching $143.74M over the same period.The EPS is expected to grow by 23.78% this year, but quarterly earnings will post 24.24% year-over-year. Quarterly sales are estimated to grow 12.83% in year-over-year returns.
Ultragenyx Pharmaceutical Inc (RARE) Top Institutional Holders
430.0 institutions hold shares in Ultragenyx Pharmaceutical Inc (RARE), with institutional investors hold 101.08% of the company’s shares. The shares outstanding are 92.24M, and float is at 83.36M with Short Float at 4.46%. Institutions hold 97.42% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 9.78 million shares valued at $401.98 million. The investor’s holdings represent 11.6039% of the RARE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.6 million shares valued at $230.3 million to account for 6.648 of the shares outstanding. The other top investors are SANDS CAPITAL MANAGEMENT, LLC which holds 5.35 million shares representing 6.353% and valued at over $220.08 million, while WELLINGTON MANAGEMENT GROUP LLP holds 5.4056 of the shares totaling 4.56 million with a market value of $187.26 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Activity
The most recent transaction is an insider sale by KAKKIS EMIL D, the company’s President & CEO. SEC filings show that KAKKIS EMIL D sold 11,727 shares of the company’s common stock on Dec 30 ’24 at a price of $42.23 per share for a total of $0.5 million. Following the sale, the insider now owns 2.18 million shares.
Still, SEC filings show that on Dec 10 ’24, KAKKIS EMIL D (President & CEO) disposed off 8,273 shares at an average price of $50.00 for $0.41 million. The insider now directly holds 2,195,712 shares of Ultragenyx Pharmaceutical Inc (RARE).
